Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Catalyst Pharmaceutical Partners, Inc. to Contact the Firm
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 10/29/13 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX) of the December 24, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Catalyst and certain executives.
A complaint has been filed on behalf of all persons who purchased Catalyst securities between October 31, 2012 and October 18, 2013 (the "Class Period") in the Southern District of Florida.
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that throughout the Class Period Catalyst issued false and/or misleading statements and failed to disclose material facts regarding Firdapse, a drug candidate that the Company purported would be used to treat Lambert-Eaton Myasthenic Syndrome ("LEMS").
In fact, prior to the market open on October 18, 2013, an article in The Street revealed that another pharmaceutical company has provided an equivalent drug free of charge for the past 20 years.
Following this news, the Company's stock declined $0.71 per share, or over 27%, to close at $1.90 per share on October 18, 2013.
If you invested in Catalyst stock or options between October 31, 2012 and October 18, 2013 and would like to discuss your legal rights, visit . You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to or . Faruqi & Faruqi, LLP also encourages anyone with information regarding Catalyst's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at or on Facebook at .
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2013 - 15:05 Uhr
Sprache: Deutsch
News-ID 1277295
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 124 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Catalyst Pharmaceutical Partners, Inc. to Contact the Firm
"
steht unter der journalistisch-redaktionellen Verantwortung von
Catalyst Pharmaceutical Partners, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
